Ximing Yuan

Adjunct professor and chief physician

Linköping University Hospital
Country flagSweden

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ximing Yuan is an Adjunct Professor and Chief Physician at Linköping University Hospital in Sweden. His research focuses on aspects of atherosclerosis, iron metabolism, and the effects of environmental factors on cellular health. Recent publications include studies on elevated Hepcidin expression in human atheroma, lysosomal dysfunction induced by Imidacloprid, and the role of CD74 in macrophage apoptosis and inflammation.

Articles (7)

Hepcidin is upregulated by increased body iron stores and inflammatory cytokines. It is associated with cardiovascular events, arterial stiffness, and increased iron accumulation in human atheroma with hemorrhage. However, it is unknown whether the expression of hepcidin in human carotid plaques is related to plaque severity and whether hepcidin expression differs between men and women. Carotid samples from 58 patients (38 males and 20 females) were immunostained with hepcidin, macrophages, ferritin, and transferrin receptor. Immunocytochemistry of hepcidin was performed on THP-1 macrophages exposed to iron or 7betahydroxycholesterol. Hepcidin expression significantly increases with the progression of human atherosclerotic plaques. Plaques of male patients have significantly higher levels of hepcidin. Expressions of hepcidin are significantly correlated with the accumulation of CD68-positive macrophages and transferrin receptor 1 (TfR1) and apoptosis. In vitro, hepcidin is significantly increased in macrophages exposed to iron and moderately increased following 7-oxysterol treatment. In the cultured cells, suppression of hepcidin protected against macrophage cell death, lysosomal membrane permeabilization, and oxidative stress. Hepcidin may play a crucial role in the development and progression of atherosclerosis. The differential expression of hepcidin in male and female patients and its significant correlations with plaque severity, highlight the potential of hepcidin as a biomarker for risk stratification and therapeutic targeting in atherosclerosis.

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (4)

Michael Sherratt

The University of Manchester

UNITED KINGDOM
View details

Alexander Eckersley

The University of Manchester

UNITED KINGDOM
View details

Andrew Trafford

The University of Manchester

UNITED KINGDOM
View details

Wei Li

Linköping University

SWEDEN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.